The Spectrum of Genetic Defects in Congenital Adrenal Hyperplasia in the Population of Cyprus: A Retrospective Analysis

Abstract

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is caused by mutations in the CYP21A2 gene. The study refers to CAH patients of Greek-Cypriot ancestry between years 2007 and 2018. One hundred and twenty patients with various degrees of CAH were categorized and genotyped. The patients were categorized in 4 mutation groups based on their clinical and biochemical findings. The majority of patients (85.0%) belonged to the non-classic (NC)-CAH form and the disorder was more often diagnosed in females (71.7%). The most severe classic salt-wasting (SW) form was identified in 11 neonates (9.2%). Seven (5.8%) children were also identified with the simple virilizing (SV) form and a median presentation age of 5 years [interquartile range (IQR) 3.2–6.5]. In the 240 nonrelated alleles, the most frequent mutation was p.Val281Leu (60.0%) followed by c.655 A/C>G (IVS2–13A/C>G) (8.8%), p.Pro453Ser (5.8%), DelEx1–3 (4.6%), p.Val304Met (4.6%), and p.Gln318stop (4.2%). Other less frequent mutations including rare deletions were also identified. Following our recent report that the true carrier frequency of CYP21A2 in Greek-Cypriots is 1:10, this study reports that the CAH prevalence is predicted around 1.7 cases per 10 000 people. Therefore, the up-to-date 120 CAH patients identified by our group make only the 6.9% of the ones estimated (approximately 1750) to exist in the Greek Cypriot population. The compiled data from a coherent population such as the Greek-Cypriot could be valuable for the antenatal diagnosis, management and genetic counselling of the existing and prospect families with CAH.

Key words

congenital adrenal hyperplasia - CYP21A2 - 21-hyrdroxylase deficiency

• References

• 1 Speiser PW, Dupont J, Zhu D. et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 90: 584-595
• 2 White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291
• 3 Wedell A, Thilen A, Ritzen EM. et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: Implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994; 78: 1145-1152
• 4 Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord 2009; 10: 77-82
• 5 New MI, Abraham M, Gonzalez B. et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci USA 2013; 110: 2611-2616
• 6 Haider S, Islam B, D'Atri V. et al. Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia. Proc Natl Acad Sci USA 2013; 110: 2605-2610
• 7 Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365: 2125-2136
• 8 Fitness J, Dixit N, Webster D. et al. Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84: 960-966
• 9 Baumgartner-Parzer SM, Nowotny P, Heinze G. et al. Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population. J Clin Endocrinol Metab 2005; 90: 775-778
• 10 Phedonos AA, Shammas C, Skordis N. et al. High carrier frequency of 21-hydroxylase deficiency in Cyprus. Clin Genet 2013; 84: 585-588
• 11 Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 181-192
• 12 Balsamo A, Baldazzi L, Menabo S. et al. Impact of molecular genetics on congenital adrenal hyperplasia management. Sex Develop 2010; 4: 233-248
• 13 Concolino P, Costella A. Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene. Mol Diagn Ther 2018; 22: 261-280
• 14 Neocleous V, Ioannou YS, Bartsota M. et al. Rare mutations in the CYP21A2 gene detected in congenital adrenal hyperplasia. Clin Biochem 2009; 42: 1363-1367
• 15 Skordis N, Kyriakou A, Tardy V. et al. Molecular defects of the CYP21A2 gene in Greek-Cypriot patients with congenital adrenal hyperplasia. Horm Res Paediatr 2011; 75: 180-186
• 16 Skordis N, Shammas C, Efstathiou E. et al. Endocrine profile and phenotype-genotype correlation in unrelated patients with non-classical congenital adrenal hyperplasia. Clin Biochem 2011; 44: 959-963
• 17 Skordis N, Shammas C, Phedonos AA. et al. Genetic defects of the CYP21A2 gene in girls with premature adrenarche. J Endocrinol Invest 2015; 38: 535-539
• 18 Neocleous V, Fanis P, Phylactou LA. et al. Genotype is associated to the degree of virilization in patients with classic congenital adrenal hyperplasia. Front Endocrinol 2018; 9: 733
• 19 Neocleous V, Shammas C, Phedonos AA. et al. Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations. Indian J Endocrinol Metab 2014; 18: S72-S79
• 20 Neocleous V, Portides G, Anastasiadou V. et al. Determination of the carrier frequency of the common GJB2 (connexin-26) 35delG mutation in the Greek Cypriot population. Int J Pediatr Otorhinolaryngol 2006; 70: 1473-1477
• 21 Neocleous V, Fanis P, Toumba M. et al. Variations in the 3'UTR of the CYP21A2 Gene in heterozygous females with hyperandrogenaemia. Int J Endocrinol 2017; 8984365
• 22 Greene CN, Cordovado SK, Turner DP. et al. Novel method to characterize CYP21A2 in Florida patients with congenital adrenal hyperplasia and commercially available cell lines. Mol Genet Metab Rep 2014; 1: 312-323
• 23 Tusie-Luna MT, Traktman P, White PC. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 1990; 265: 20916-20922
• 24 Wilson RC, Mercado AB, Cheng KC. et al. Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab 1995; 80: 2322-2329
• 25 Wedell A. Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): Implications for diagnosis, prognosis and treatment. Acta Paediatr 1998; 87: 159-164
• 26 Higashi Y, Tanae A, Inoue H. et al. Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450(C21) gene: Implications for steroid 21-hydroxylase deficiency. Am J Hum Genet 1988; 42: 17-25
• 27 Rodrigues NR, Dunham I, Yu CY. et al. Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J 1987; 6: 1653-1661
• 28 Higashi Y, Hiromasa T, Tanae A. et al. Effects of individual mutations in the P-450(C21) pseudogene on the P-450(C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem 1991; 109: 638-644
• 29 Amor M, Parker KL, Globerman H. et al. Mutation in the CYP21B gene (Ile-172–Asn) causes steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA 1988; 85: 1600-1604
• 30 Barbaro M, Baldazzi L, Balsamo A. et al. Functional studies of two novel and two rare mutations in the 21-hydroxylase gene. J Mol Med (Berl) 2006; 84: 521-528
• 31 Lajic S, Robins T, Krone N. et al. CYP21 mutations in simple virilizing congenital adrenal hyperplasia. J Mol Med (Berl) 2001; 79: 581-586
• 32 Balsamo A, Cacciari E, Baldazzi L. et al. CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region. Clin Endocrinol (Oxf) 2000; 53: 117-125
• 33 Lekarev O, Tafuri K, Lane AH. et al. Erroneous prenatal diagnosis of congenital adrenal hyperplasia owing to a duplication of the CYP21A2 gene. J Perinatol 2013; 33: 76-78
• 34 Speiser PW, Arlt W, Auchus RJ. et al. Congenital Adrenal Hyperplasia Due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018; 103: 4043-4088
• 35 Meyer-Bahlburg HFL, Khuri J, Reyes-Portillo J. et al. Stigma associated with classical congenital adrenal hyperplasia in women’s sexual lives. Arch Sex Behav 2018; 47: 943-951
• 36 Bachelot A, Grouthier V, Courtillot C. et al. Management of endocrine disease: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Update on the management of adult patients and prenatal treatment. Eur J Endocrinol 2017; 176: R167-R181
• 37 Gidlof S, Falhammar H, Thilen A. et al. One hundred years of congenital adrenal hyperplasia in Sweden: A retrospective, population-based cohort study. Lancet Diabetes Endocrinol 2013; 1: 35-42
• 38 Arlt W, Willis DS, Wild SH. et al. Health status of adults with congenital adrenal hyperplasia: A cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95: 5110-5121
• 39 El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet 2017; 390: 2194-2210
• 40 Parsa AA, New MI. Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 2017; 165: 2-11
• 41 Shammas C, Neocleous V, Toumba M. et al. Overview of genetic defects in endocrinopathies in the island of Cyprus; Evidence of a founder effect. Genet Test Mol Biomark 2012; 16: 1073-1079
• 42 Wilson RC, Nimkarn S, Dumic M. et al. Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21–hydroxylase deficiency. Mol Genet Metab 2007; 90: 414-421
• 43 Ayalon-Dangur I, Segev-Becker A, Ayalon I. et al. The many faces of non-classic congenital adrenal hyperplasia. Isr Med Assoc J 2017; 19: 317-322
• 44 Eyal O, Tenenbaum-Rakover Y, Shalitin S. et al. Adult height of subjects with nonclassical 21-hydroxylase deficiency. Acta Paediatr 2013; 102: 419-423
• 45 Neocleous V, Shammas C, Phedonos AP. et al. Genetic defects in the cyp21a2 gene in heterozygous girls with premature adrenarche and adolescent females with hyperandrogenemia. Georgian Med News 2012; 40-47
• 46 Dracopoulou-Vabouli M, Maniati-Christidi M, Dacou-Voutetakis C. The spectrum of molecular defects of the CYP21 gene in the Hellenic population: Variable concordance between genotype and phenotype in the different forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 2845-2848
• 47 Sadeghi F, Yurur-Kutlay N, Berberoglu M. et al. Identification of frequency and distribution of the nine most frequent mutations among patients with 21-hydroxylase deficiency in Turkey. J Pediatr Endocrinol Metab 2008; 21: 781-787
• 48 Ezquieta B, Oliver A, Gracia R. et al. Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. Hum Genet 1995; 96: 198-204
• 49 Carrera P, Bordone L, Azzani T. et al. Point mutations in Italian patients with classic, non-classic, and cryptic forms of steroid 21-hydroxylase deficiency. Hum Genet 1996; 98: 662-665
• 50 Lee HH. The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency. J Hum Genet 2004; 49: 65-72
• 51 Concolino P, Mello E, Minucci A. et al. A new CYP21A1P/CYP21A2 chimeric gene identified in an Italian woman suffering from classical congenital adrenal hyperplasia form. BMC Med Genet 2009; 10: 72